KIR2DS3 is associated with protection against acute myeloid leukemia

Iranian Journal of Immunology

Volumn 7, Issue 1, 2010, Pages 8-17

  Shahsavar, Farhad ^a,b   Tajik, Nader ^a   Entezami, Kobra Zinat ^a   Radjabzadeh, Masoomeh Fallah ^a   Asadifar, Behnam ^a   Alimoghaddam, Kamran ^c   Dahaghi, Mohammadreza Ostadali ^c   Jalali, Arash ^c,d   Ghashghaie, Andisheh ^c   Ghavamzadeh, Ardeshir ^c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute leukemia; Genotype; HLA; KIR

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; INHERITANCE; IRAN; KIR2DS3 GENE; MAJOR CLINICAL STUDY; MALE; PROTECTION; SCHOOL CHILD; TUMOR IMMUNITY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MIDDLE AGED; NATURAL KILLER CELL; TUMOR ESCAPE;

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KIR2DS3 PROTEIN, HUMAN; LIGAND;

ADOLESCENT; ADULT; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LIGANDS; MALE; MIDDLE AGED; RECEPTORS, KIR; TUMOR ESCAPE;

EID: 77955070943     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Barao I, Murphy WJ. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant. 2003; 9:727-41.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989; 47:187-376.
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17:189-220.
4. French AR, Yokoyama WM. Natural killer cells and viral infections. Curr Opin Immunol. 2003; 15:45-51.
5. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002; 188:9-21.
6. Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, et al. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia. 1996; 10:1758-64.
7. Lotzová E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res. 1987; 11:1059-66.
8. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005; 5:201-14.
9. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A. 1993; 90:12000-4.
10. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. Molecular clones of the p58 NK cell receptor re-veal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity. 1995; 2:439-449.
11. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 1997; 158:4026-8.
12. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998; 161:571-7.
13. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995; 181:1133-44.
14. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994; 180:1235-42.
15. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, et al. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007; 178:33-7.
16. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med. 1996; 184:505-18.
17. Döhring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol. 1996; 156:3098-101.
18. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005; 175:5222-9.
19. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier LL, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 1997; 158:5237-41.
20. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol. 1997; 27:3095-9.
21. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005; 102:13224-9.
22. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity. 2001; 15:363-74.
23. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000; 97:4778-83.
24. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990; 11:237-44.
25. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002; 169:5118-29.
26. Middleton D, Gonzalez A, Gilmore PM. Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol. 2008; 68:128-34.
27. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004; 103:3122-30.
28. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholts JD, et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol. 2002; 63:200-10.
29. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, et al. Expression of human leucocyte antigens and costimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol. 2003; 120:1000-8.
30. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986; 319:675-8.
31. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1997; 74:1-6.
32. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999; 94:333-9.
33. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell allore-activity in mismatched hematopoietic transplants. Science. 2002; 295:2097-100.
34. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia. 2004; 18:2002-7.
35. Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007; 59:1-15.
36. Middleton D, Diler AS, Meenagh A, Sleator C, Gourraud PA. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 2009; 73:553-60.
37. Tajik N, Shahsavar F, Nasiri MR, Radjabzadeh MF. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay. International Journal of Immunogenetics. doi: 10.1111/j.1744-313X.2010.00906.x
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215.
39. Tajik N, Shahsavar F, Mousavi T, Radjabzadeh MF. Distribution of KIR genes in the Iranian population. Tissue Antigens. 2009; 74:22-31.
40. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007; 68:309-23.
41. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004; 103:3122-30.
42. Elkins WL, Pickard A, Pierson GR. Deficient expression of class-I HLA in some cases of acute leukemia. Cancer Immunol Immunother. 1984; 18:91-100.
43. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholts JD, et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol. 2002; 63:200-10.
44. Verheyden S, Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia. 2006; 20:1437-8.
45. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell allore-activity in mismatched hematopoietic transplants. Science. 2002; 295:2097-100.
46. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009; 113:726-32.